Cross‐Linking of Thiolated Paclitaxel–Oligo(p‐phenylene vinylene) Conjugates Aggregates inside Tumor Cells Leads to “Chemical Locks” That Increase Drug Efficacy

How to reduce the resistance of certain tumor cells to paclitaxel (PTX) and related taxoid anticancer drugs is a major challenge for improving cure rates. An oligo(p‐phenylenevinylene) unit with thiol groups and a PTX unit (OPV‐S‐PTX), which enhances drug efficacy and reverses resistance is thus designed. The mechanism involves diffusion of OPV‐S‐PTX into the cell, where π–π interactions lead to aggregation. Cross‐linking of the aggregates via oxidation of thiol groups is favored in tumor cells because of the higher reactive oxygen species (ROS) concentration. Cross‐linked aggregates “chemically lock” the multichromophore particle for a more persistent effect. The IC₅₀ of OPV‐S‐PTX for tumor cell line A549 is reduced down to 0.33 × 10^?9m from that observed for PTX itself (41 × 10^?9m ). Enhanced efficacy by OPV‐S‐PTX is proposed to proceed via acceleration of microtubule bundle formation. A549/T‐inoculated xenograft mice experiments reveal suppression of tumor growth upon OPV‐S‐PTX treatment. Altogether, these results show that the internal cross‐linking of OPV‐S‐PTX through ROS provides a means to discriminate between tumor and healthy cells and the formation of the chemically locked particles enhances drug efficacy and helps in reducing resistance.